JPMorgan Quants Say Sudden Earnings Gloom Spells Market Trouble

(Bloomberg) — Expectations about corporate earnings growth are quickly diminishing, JPMorgan Chase & Co. quant strategists said, warning that the gloom could spell more trouble for global stock markets after an underwhelming start to the year.

“Yes, there are still net upgrades, but the pace of these upgrades are very quickly nearing net EPS downgrade territory,” quant strategists led by Khuram Chaudhry wrote in a note. Such earnings-per-share cuts “frequently lead to major shifts in risk/reward and increasing equity market volatility,” he said.

Following a rout triggered by expectations that central banks will tighten policy more aggressively than previously anticipated to tame surging inflation, bulls have pointed to company fundamentals to back their case for more upside to global equities. Still, while earnings are still coming in above expectations, the pace of growth has moderated and guidance from company management has been turning more pessimistic.

“Upgrades persist in the U.S, Europe, and for the world,” Chaudhry said. “However, the pace of these upgrades is quickly diminishing, and the earnings landscape is weakening,” he added, as he singled out Japan as the region with the largest upgrades in earnings expectations.

JPMorgan’s equity team has been among the most optimistic voices on Wall Street about the outlook for global stock markets. Bears, such as Bank of America Corp.’s Michael Hartnett, reiterated on Friday that the rising “rates shock” will morph into “recession shock,” and advised a short position in equities.

Not everyone shares the gloom. The recent pullback in risk assets won’t turn into a bear market that’s reflective of a recession, Peter Oppenheimer, chief global equity strategist at Goldman Sachs Group Inc., said in an interview with Bloomberg TV. “We’re still going to see economic activity continue through the course of this year.”

©2022 Bloomberg L.P.

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More